« Return to News | R&D Trends

Biogen Idec, Adimab expand collaboration

Friday, July 26, 2013 03:05 PM

Adimab, a provider of an integrated antibody discovery and optimization platform, has expanded its collaboration with Biogen Idec for the discovery of antibody-based therapeutics. 

Adimab will license and transfer its proprietary antibody discovery platform to Biogen Idec and enable Biogen Idec researchers to utilize the Adimab technology for the discovery and optimization of all antibody formats, including bispecific antibodies.  Biogen Idec will receive a custom antibody library and will obtain a license to the Adimab Platform for use in its targeted therapeutic areas. Following GSK, Biogen Idec will be the second pharmaceutical company to internalize the Adimab platform. In addition, Biogen Idec has secured an option to receive continued improvements to the Adimab Platform, including access to new antibody libraries.

Over the past four years, Adimab has established collaborations with multiple pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead, Kyowa Hakko Kirin and GSK. Adimab's collaborations range from single-target funded discovery projects to larger, multi-target funded discovery collaborations, as well as full license, transfer and enablement of the Adimab Platform to pharma companies. These collaborations focus on IgG discovery, optimization, humanization and/or bispecifics for therapeutic products.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.